HAINS MYCOBACTERIUM TUBERCULOSIS SECOND LINE DRUG RESISTANCE PROFILE Test
Test Cost: AED 1050.0
Symptoms and Diagnosis
If you suspect Mycobacterium tuberculosis infection and want to determine the drug resistance profile, the HAINS MYCOBACTERIUM TUBERCULOSIS SECOND LINE DRUG RESISTANCE PROFILE Test is a recommended option. This test helps in identifying the presence of drug-resistant strains of M. tuberculosis, allowing healthcare providers to tailor the treatment regimen accordingly.
Test Details
The HAINS (Hybridization in Aminoacyl-tRNA Synthetase) assay is a molecular diagnostic test used to determine the drug resistance profile of Mycobacterium tuberculosis (M. tuberculosis) to second-line drugs. This test specifically targets mutations in the genes associated with resistance to second-line drugs, such as fluoroquinolones (e.g., moxifloxacin, levofloxacin), aminoglycosides (e.g., amikacin, kanamycin), and injectable drugs (e.g., capreomycin).
The HAINS assay involves the extraction of DNA from M. tuberculosis isolates, followed by amplification of specific target regions using polymerase chain reaction (PCR). The amplified DNA is then hybridized with specific probes that are complementary to wild-type and mutant sequences associated with drug resistance. The hybridized DNA is detected using a colorimetric or fluorescence-based method.
The HAINS assay provides information on the presence or absence of specific mutations associated with drug resistance. This allows healthcare providers to tailor the treatment regimen for M. tuberculosis infections based on the individual’s drug resistance profile. It helps in selecting the most effective combination of antibiotics to achieve successful treatment outcomes and prevent the further spread of drug-resistant strains.
Test Components and Price
The HAINS MYCOBACTERIUM TUBERCULOSIS SECOND LINE DRUG RESISTANCE PROFILE Test costs AED 1050.0.
Sample Condition
Submit 3 mL (2 mL min.) of sputum, bronchoalveolar lavages, bronchial aspirates, or cultured growth on appropriate media in a sterile screw capped container. Place the container in a sealed plastic bag and ship refrigerated. DO NOT FREEZE.
Report Delivery
If the sample is received by 11 am, the report will be delivered on Friday.
Method
The HAINS MYCOBACTERIUM TUBERCULOSIS SECOND LINE DRUG RESISTANCE PROFILE Test is conducted using the PCR (Polymerase Chain Reaction) and Line Probe Assay methods.
Test Type
The HAINS MYCOBACTERIUM TUBERCULOSIS SECOND LINE DRUG RESISTANCE PROFILE Test is specifically designed to detect tuberculosis.
Doctor
This test can be ordered by a physician.
Test Department
This test is conducted by the Molecular Diagnostics department at DNA Labs UAE.
Pre Test Information
No special preparation is required before taking this test.
| Test Name | HAINS MYCOBACTERIUM TUBERCULOSIS SECOND LINE DRUG RESISTANCE PROFILE Test |
|---|---|
| Components | |
| Price | 1050.0 AED |
| Sample Condition | Submit 3 mL (2 mL min.) Sputum\/ bronchoalveolar lavages \/ bronchial aspirates \/ Cultured growth on appropriate media in a sterile screw capped container in a sealed plastic bag. Ship refrigerated. DO NOT FREEZE. |
| Report Delivery | Sample Sat by 11 am, Report Fri |
| Method | PCR, Line probe assay |
| Test type | Tuberculosis |
| Doctor | Physician |
| Test Department: | MOLECULAR DIAGNOSTICS |
| Pre Test Information | No special preparation required |
| Test Details | The HAINS (Hybridization in Aminoacyl-tRNA Synthetase) assay is a molecular diagnostic test used to determine the drug resistance profile of Mycobacterium tuberculosis (M. tuberculosis) to second-line drugs. This test specifically targets mutations in the genes associated with resistance to second-line drugs, such as fluoroquinolones (e.g., moxifloxacin, levofloxacin), aminoglycosides (e.g., amikacin, kanamycin), and injectable drugs (e.g., capreomycin). The HAINS assay involves the extraction of DNA from M. tuberculosis isolates, followed by amplification of specific target regions using polymerase chain reaction (PCR). The amplified DNA is then hybridized with specific probes that are complementary to wild-type and mutant sequences associated with drug resistance. The hybridized DNA is detected using a colorimetric or fluorescence-based method. The HAINS assay provides information on the presence or absence of specific mutations associated with drug resistance. This allows healthcare providers to tailor the treatment regimen for M. tuberculosis infections based on the individual’s drug resistance profile. It helps in selecting the most effective combination of antibiotics to achieve successful treatment outcomes and prevent the further spread of drug-resistant strains. |
